What is Eli Lilly and Company's earnings per share (EPS)?

Eli Lilly and Company (LLY) reported diluted earnings per share of $22.95 for fiscal year 2025. This represents a 96.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Eli Lilly and Company (LLY) Financials

LLY

Trailing 12 months to June 30, 2026

Revenue $79.7B +49.6% YoY

Net Income $26.7B +93.6% YoY

EPS (Diluted) $29.80 +94.8% YoY

Operating Cash Flow $28.1B +156.7% YoY

Market Cap $1.1T as of Oct 10, 2026

Price / Sales 13.2x on $79.7B revenue, trailing 12 months to June 30, 2026

Price / Earnings 39.4x on $26.7B net income, trailing 12 months to June 30, 2026

Price / Book 31.0x on $33.9B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LLY SEC filings page.

Eli Lilly and Company (LLY) reported $79.7B in revenue over the twelve months to Jun 30, 2026, up 49.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LLY FY2025 2026-10-03

Eli Lilly’s recent expansion is converting sales into profit and operating cash faster than sales are growing, while equity strengthens the balance sheet.

From FY2023 to FY2025, revenue nearly doubled while net income and operating cash flow almost quadrupled; gross margin also moved from 79.3% to 83.0%. This pairing points to improved earnings conversion and a more favorable cost or product mix, not merely more volume, although the absent operating-income line prevents isolating which below-gross-profit costs drove the change.

Operating cash flow rose from $4.2B in FY2023 to $16.8B in FY2025, broadly tracking the increase in net income rather than lagging it. With R&D rising from $9.3B to $13.3B over the same span, the business is funding more research while sales growth absorbs that spending more efficiently.

The balance sheet became less leverage-dependent despite expansion: equity nearly doubled from FY2024 to FY2025, while debt-to-equity fell from 2.0x to 1.5x despite higher long-term debt. The current ratio improved from 1.2x to 1.6x, indicating better reported short-term coverage alongside growth.

Financial Health Signals

Financial health score not available

Eli Lilly and Company does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Strong

7/9

Eli Lilly and Company passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.81x

For every $1 of reported earnings, Eli Lilly and Company generates $0.81 in operating cash flow ($16.8B OCF vs $20.6B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$23.0B

YoY+47.7%

QoQ+16.0%

5Y CAGR+27.8%

10Y CAGR+15.6%

Eli Lilly and Company generated $23.0B in revenue in Q2 2026. This represents an increase of 47.7% from the same quarter a year earlier. Against the prior quarter it is up 16.0%.

Net Income

$7.1B

YoY+25.3%

QoQ-4.1%

5Y CAGR+38.5%

10Y CAGR+25.2%

Eli Lilly and Company reported $7.1B in net income in Q2 2026. This represents an increase of 25.3% from the same quarter a year earlier. Against the prior quarter it is down 4.1%.

EPS (Diluted)

$7.94

YoY+26.2%

QoQ-3.9%

5Y CAGR+39.0%

10Y CAGR+27.3%

Eli Lilly and Company earned $7.94 per diluted share (EPS) in Q2 2026. This represents an increase of 26.2% from the same quarter a year earlier. Against the prior quarter it is down 3.9%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$8.9B

YoY+165.1%

QoQ+69.4%

5Y CAGR+22.7%

Eli Lilly and Company held $8.9B in cash against $47.9B in long-term debt as of Q2 2026.

Dividends Per Share

$3.46

YoY+15.3%

Eli Lilly and Company paid $3.46 per share in dividends in Q2 2026. This represents an increase of 15.3% from the same quarter a year earlier.

Shares Outstanding

941M

YoY-0.5%

QoQ0.0%

5Y CAGR-0.3%

10Y CAGR-1.6%

Eli Lilly and Company had 941M shares outstanding in Q2 2026. This represents a decrease of 0.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Margins & Returns

Gross Margin

85.8%

YoY+1.5pp

QoQ+3.8pp

5Y change+14.8pp

10Y change+12.9pp

Eli Lilly and Company's gross margin was 85.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.

Net Margin

30.9%

YoY-5.5pp

QoQ-6.5pp

5Y change+10.3pp

10Y change+17.1pp

Eli Lilly and Company's net profit margin was 30.9% in Q2 2026, showing the share of revenue converted to profit. This is down 5.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.5 percentage points.

Return on Equity

20.9%

YoY-10.0pp

QoQ-2.8pp

5Y change-0.6pp

10Y change+15.8pp

Eli Lilly and Company's ROE was 20.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 10.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.

Operating Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$3.8B

YoY+14.5%

QoQ+8.8%

5Y CAGR+18.2%

Eli Lilly and Company invested $3.8B in research and development in Q2 2026. This represents an increase of 14.5% from the same quarter a year earlier. Against the prior quarter it is up 8.8%.

Share Buybacks

$1.6B

YoY+131.4%

QoQ-32.0%

5Y CAGR+26.2%

Eli Lilly and Company spent $1.6B on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 131.4% from the same quarter a year earlier. Against the prior quarter it is down 32.0%.

Capital Expenditures

Not reported for Q2 2026.

LLY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LLY quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$79.7B	$65.2B+44.7%	$45.0B+32.0%	$34.1B+19.6%	$28.5B+0.8%	$28.3B+15.4%	$24.5B+9.9%	$22.3B+3.8%	$21.5B+7.6%	$20.0B+9.1%	$18.3B-8.2%	$20.0B+1.7%	$19.6B-15.1%	$23.1B+2.3%	$22.6B-6.9%	$24.3B
Cost of Revenue	$13.2B	$11.1B+31.3%	$8.4B+18.9%	$7.1B+6.8%	$6.6B-9.3%	$7.3B+33.4%	$5.5B+16.1%	$4.7B+0.8%	$4.7B+5.3%	$4.4B+6.9%	$4.2B-17.4%	$5.0B+2.1%	$4.9B+0.5%	$4.9B+2.3%	$4.8B-5.4%	$5.1B
Gross Profit	$66.4B	$54.1B+47.8%	$36.6B+35.4%	$27.0B+23.4%	$21.9B+4.3%	$21.0B+10.2%	$19.1B+8.3%	$17.6B+4.7%	$16.8B+8.3%	$15.5B+9.7%	$14.2B-5.2%	$14.9B+1.6%	$14.7B-19.3%	$18.2B+2.2%	$17.8B-7.3%	$19.2B
R&D Expenses	$14.6B	$13.3B+21.3%	$11.0B+18.0%	$9.3B+29.5%	$7.2B+3.8%	$6.9B+16.0%	$6.0B+6.8%	$5.6B+10.8%	$5.1B-0.9%	$5.1B+1.1%	$5.0B+5.1%	$4.8B+1.3%	$4.7B-14.4%	$5.5B+4.8%	$5.3B+5.1%	$5.0B
SG&A Expenses	$12.2B	$11.1B+29.1%	$8.6B+16.1%	$7.4B+15.0%	$6.4B+0.1%	$6.4B+5.1%	$6.1B-1.5%	$6.2B+4.0%	$6.0B-0.1%	$6.0B+2.4%	$5.8B-10.6%	$6.5B-1.3%	$6.6B-7.1%	$7.1B-5.2%	$7.5B-4.6%	$7.9B
Interest Expense	N/A	$895.0M+14.6%	$781.0M+60.7%	$485.9M+46.5%	$331.6M-2.4%	$339.8M-5.5%	$359.6M-10.2%	$400.6M+65.2%	$242.5M+7.8%	$225.0M+21.5%	$185.2M+14.9%	$161.2M+8.3%	$148.8M-7.1%	$160.1M-10.0%	$177.8M-4.4%	$186.0M
Income Tax	$6.9B	$5.1B+143.6%	$2.1B+59.1%	$1.3B+134.0%	$561.6M-2.1%	$573.8M-44.6%	$1.0B+65.0%	$628.0M+18.6%	$529.5M-77.9%	$2.4B+333.7%	$551.4M+44.5%	$381.6M-37.4%	$609.8M-49.4%	$1.2B-8.7%	$1.3B+31.7%	$1.0B
Net Income	$26.7B	$20.6B+94.9%	$10.6B+102.1%	$5.2B-16.1%	$6.2B+11.9%	$5.6B-9.9%	$6.2B-25.5%	$8.3B+157.4%	$3.2B+1683.5%	-$204.1M-107.5%	$2.7B+13.7%	$2.4B+0.7%	$2.4B-49.0%	$4.7B+14.6%	$4.1B-6.0%	$4.3B
EPS (Basic)	N/A	$23.00+95.6%	$11.76+102.1%	$5.82-16.0%	$6.93+12.7%	$6.15-9.8%	$6.82-23.6%	$8.93+184.4%	$3.14+1752.6%	-$0.19-107.3%	$2.59+14.1%	$2.27+1.8%	$2.23-48.5%	$4.33+18.0%	$3.67-5.9%	$3.90
EPS (Diluted)	$29.80	$22.95+96.0%	$11.71+101.9%	$5.80-15.9%	$6.90+12.7%	$6.12-9.9%	$6.79-23.6%	$8.89+184.0%	$3.13+1747.4%	-$0.19-107.4%	$2.58+14.2%	$2.26+1.3%	$2.23-48.4%	$4.32+18.0%	$3.66-6.2%	$3.90
Diluted Shares (Avg)	N/A	899M-0.5%	904M+0.1%	903M-0.1%	905M-0.8%	912M-0.1%	913M-2.5%	936M-9.5%	1.03B-1.7%	1.05B-0.9%	1.06B-0.4%	1.07B-0.8%	1.07B-1.0%	1.08B-2.9%	1.12B+0.3%	1.11B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$23.0B+47.7%	$19.8B+55.5%	$19.3B+42.5%	$17.6B+53.9%	$15.6B+37.6%	$12.7B+45.2%	$13.5B+44.7%	$11.4B+20.4%
Cost of Revenue	$3.3B+33.5%	$3.6B+60.8%	$3.4B+40.2%	$3.0B+38.6%	$2.4B+12.8%	$2.2B+33.0%	$2.4B+34.4%	$2.2B+16.7%
Gross Profit	$19.7B+50.3%	$16.2B+54.4%	$15.9B+43.0%	$14.6B+57.4%	$13.1B+43.6%	$10.5B+48.1%	$11.1B+47.1%	$9.3B+21.3%
R&D Expenses	$3.8B+14.5%	$3.5B+28.4%	$3.8B+25.8%	$3.5B+26.8%	$3.3B+23.0%	$2.7B+8.4%	$3.0B+18.0%	$2.7B+13.5%
SG&A Expenses	$3.4B+24.6%	$2.9B+18.9%	$3.1B+29.2%	$2.7B+30.5%	$2.8B+30.0%	$2.5B+26.4%	$2.4B+25.9%	$2.1B+16.4%
Interest Expense	N/A	N/A	$222.7M-1.1%	$179.6M-6.8%	$249.0M+35.6%	$243.7M+35.7%	$225.1M+62.9%	$192.7M+54.7%
Income Tax	$2.2B+92.8%	$1.5B+108.6%	$1.6B+159.0%	$1.6B+166.9%	$1.1B+102.8%	$697.0M+137.7%	$628.5M+97.1%	$618.1M+27.5%
Net Income	$7.1B+25.3%	$7.4B+168.1%	$6.6B+50.5%	$5.6B+475.3%	$5.7B+90.8%	$2.8B+23.0%	$4.4B+101.4%	$970.3M+1790.4%
EPS (Basic)	$7.95+26.2%	$8.27+169.4%	$7.40+51.0%	$6.22+475.9%	$6.30+91.5%	$3.07+23.3%	$4.90+101.6%	$1.08+1900.0%
EPS (Diluted)	$7.94+26.2%	$8.26+169.9%	$7.39+51.4%	$6.21+480.4%	$6.29+91.8%	$3.06+23.4%	$4.88+101.7%	$1.07+1883.3%
Diluted Shares (Avg)	894M-0.7%	896M-0.5%	N/A	899M-0.7%	900M-0.5%	901M-0.4%	N/A	905M+0.6%

Not reported in any period shown, so not listed: Operating Income, EBITDA.

LLY Balance Sheet

LLY quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$112.5B+42.9%	$78.7B+23.0%	$64.0B+29.3%	$49.5B+1.4%	$48.8B+4.7%	$46.6B+18.7%	$39.3B-10.5%	$43.9B-2.4%	$45.0B+15.9%	$38.8B+9.1%	$35.6B-2.0%	$36.3B+3.0%	$35.2B+2.5%	$34.4B+2.2%	$33.7B
Current Assets	$55.6B+69.9%	$32.7B+27.3%	$25.7B+42.7%	$18.0B-2.3%	$18.5B+5.7%	$17.5B+27.4%	$13.7B-33.3%	$20.5B+7.0%	$19.2B+27.2%	$15.1B+20.1%	$12.6B+5.4%	$11.9B-9.0%	$13.1B+0.5%	$13.0B-8.5%	$14.2B
Cash & Equivalents	$7.3B+122.4%	$3.3B+15.9%	$2.8B+36.4%	$2.1B-45.9%	$3.8B+4.4%	$3.7B+56.5%	$2.3B-68.1%	$7.3B+17.9%	$6.2B+35.6%	$4.6B+25.0%	$3.7B-5.3%	$3.9B+1.1%	$3.8B-4.7%	$4.0B-32.1%	$5.9B
Short-Term Investments	$0-100.0%	$154.8M+41.9%	$109.1M-24.7%	$144.8M+60.7%	$90.1M+272.3%	$24.2M-76.0%	$101.0M+14.5%	$88.2M-94.1%	$1.5B+2.8%	$1.5B+85.4%	$785.4M-17.8%	$955.4M-39.0%	$1.6B-5.9%	$1.7B+70.9%	$974.6M
Inventory	$13.7B+81.1%	$7.6B+31.5%	$5.8B+33.9%	$4.3B+10.9%	$3.9B-2.4%	$4.0B+24.7%	$3.2B+3.0%	$3.1B-8.8%	$3.4B-4.7%	$3.6B+3.4%	$3.4B+25.8%	$2.7B-6.4%	$2.9B+10.8%	$2.6B+15.0%	$2.3B
Accounts Receivable	$17.8B+61.4%	$11.0B+21.1%	$9.1B+31.8%	$6.9B+3.3%	$6.7B+13.6%	$5.9B+29.2%	$4.5B-1.0%	$4.6B+15.5%	$4.0B-1.3%	$4.0B+14.7%	$3.5B+8.6%	$3.2B-5.8%	$3.4B+2.9%	$3.3B-7.3%	$3.6B
Long-Term Investments	$2.8B-12.9%	$3.2B+5.4%	$3.1B+5.2%	$2.9B-9.7%	$3.2B+8.3%	$3.0B+51.2%	$2.0B-2.1%	$2.0B-64.6%	$5.7B+8.8%	$5.2B+42.8%	$3.6B-20.2%	$4.6B-40.1%	$7.6B+20.8%	$6.3B+56.7%	$4.0B
Goodwill	$5.9B+2.2%	$5.8B+16.8%	$4.9B+21.3%	$4.1B+4.7%	$3.9B+3.3%	$3.8B+2.4%	$3.7B+169.2%	$1.4B-0.8%	$1.4B-65.3%	$4.0B-1.7%	$4.0B+129.8%	$1.8B+15.9%	$1.5B+1.0%	$1.5B+4.6%	$1.4B
Total Liabilities	$85.9B+33.4%	$64.4B+21.1%	$53.2B+37.1%	$38.8B-2.5%	$39.8B-2.8%	$41.0B+11.8%	$36.7B+7.6%	$34.1B+2.1%	$33.4B+34.6%	$24.8B+18.1%	$21.0B+0.3%	$20.9B+18.8%	$17.6B-10.3%	$19.6B-2.4%	$20.1B
Current Liabilities	$35.2B+24.1%	$28.4B+4.0%	$27.3B+59.3%	$17.1B+13.9%	$15.1B+20.6%	$12.5B+6.0%	$11.8B-0.9%	$11.9B-18.2%	$14.5B+32.3%	$11.0B+33.5%	$8.2B-15.5%	$9.7B+9.2%	$8.9B+6.3%	$8.4B-6.1%	$8.9B
Non-Current Liabilities	$50.7B+40.6%	$36.1B+39.5%	$25.8B+19.8%	$21.6B-12.3%	$24.6B-13.2%	$28.3B+14.2%	$24.8B+17.5%	$21.1B+12.4%	$18.8B+36.7%	$13.7B+7.8%	$12.7B+14.0%	$11.2B+28.6%	$8.7B-22.6%	$11.2B+0.4%	$11.2B
Long-Term Debt	$40.9B+43.3%	$28.5B+55.7%	$18.3B+24.3%	$14.7B-4.0%	$15.3B-7.5%	$16.6B+20.0%	$13.8B+50.3%	$9.2B-7.5%	$9.9B+18.8%	$8.4B+5.0%	$8.0B+49.5%	$5.3B+27.0%	$4.2B-23.9%	$5.5B+1.0%	$5.5B
Total Equity	$26.5B+85.9%	$14.3B+32.5%	$10.8B+1.1%	$10.6B+18.6%	$9.0B+59.2%	$5.6B+116.4%	$2.6B-73.5%	$9.8B-15.2%	$11.6B-17.2%	$14.0B-3.9%	$14.6B-5.2%	$15.4B-12.8%	$17.6B+19.4%	$14.8B+9.0%	$13.5B
Retained Earnings	$24.5B+80.7%	$13.5B+31.3%	$10.3B+2.7%	$10.0B+12.1%	$9.0B+14.4%	$7.8B+59.1%	$4.9B-56.8%	$11.4B-18.0%	$13.9B-13.4%	$16.0B+0.2%	$16.0B-2.9%	$16.5B-3.0%	$17.0B+5.6%	$16.1B+8.0%	$14.9B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$142.3B+41.0%	$116.6B+30.4%	$112.5B+42.9%	$114.9B+52.0%	$100.9B+40.4%	$89.4B+39.8%	$78.7B+23.0%	$75.6B+30.5%
Current Assets	$64.7B+29.7%	$54.8B+32.9%	$55.6B+69.9%	$62.1B+97.6%	$49.9B+65.1%	$41.3B+63.8%	$32.7B+27.3%	$31.4B+36.5%
Cash & Equivalents	$8.9B+165.1%	$5.3B+70.8%	$7.3B+122.4%	$9.8B+190.6%	$3.4B+4.7%	$3.1B+25.7%	$3.3B+15.9%	$3.4B+41.5%
Short-Term Investments	$0-100.0%	$0-100.0%	$0-100.0%	$121.6M-18.6%	$170.1M+21.2%	$127.4M+1.0%	$154.8M+41.9%	$149.4M+32.1%
Inventory	$16.8B+52.5%	$14.5B+56.0%	$13.7B+81.1%	$12.2B+63.3%	$11.0B+69.9%	$9.3B+52.6%	$7.6B+31.5%	$7.5B+52.2%
Accounts Receivable	$20.1B+41.7%	$18.4B+53.1%	$17.8B+61.4%	$16.1B+56.5%	$14.2B+28.5%	$12.0B+52.6%	$11.0B+21.1%	$10.3B+26.1%
Long-Term Investments	$3.9B+20.2%	$3.1B-3.3%	$2.8B-12.9%	$2.8B-12.2%	$3.2B+11.5%	$3.2B+4.4%	$3.2B+5.4%	$3.2B+18.9%
Goodwill	$8.8B+53.3%	$6.1B+6.2%	$5.9B+2.2%	$5.9B+2.2%	$5.8B0.0%	$5.8B+16.8%	$5.8B+16.8%	$5.8B+41.2%
Total Liabilities	$108.4B+31.2%	$85.4B+16.0%	$85.9B+33.4%	$91.1B+48.5%	$82.6B+41.7%	$73.6B+44.0%	$64.4B+21.1%	$61.4B+31.4%
Current Liabilities	$47.7B+22.4%	$36.6B+21.8%	$35.2B+24.1%	$40.1B+62.7%	$39.0B+43.9%	$30.1B+61.7%	$28.4B+4.0%	$24.7B+12.2%
Non-Current Liabilities	$60.7B+39.3%	$48.7B+12.1%	$50.7B+40.6%	$50.9B+39.1%	$43.6B+40.0%	$43.5B+34.0%	$36.1B+39.5%	$36.6B+48.8%
Long-Term Debt	$47.9B+40.0%	$39.4B+14.1%	$40.9B+43.3%	$40.9B+40.7%	$34.2B+44.0%	$34.5B+40.5%	$28.5B+55.7%	$29.0B+62.1%
Total Equity	$33.9B+85.4%	$31.2B+97.9%	$26.5B+85.9%	$23.8B+67.1%	$18.3B+34.7%	$15.8B+23.0%	$14.3B+32.5%	$14.2B+26.9%
Retained Earnings	$31.9B+83.5%	$29.5B+95.5%	$24.5B+80.7%	$22.3B+63.3%	$17.4B+31.9%	$15.1B+20.3%	$13.5B+31.3%	$13.6B+32.2%

LLY Cash Flow Statement

LLY quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$28.1B	$16.8B+90.7%	$8.8B+108.0%	$4.2B-44.1%	$7.6B+3.0%	$7.4B+13.3%	$6.5B+34.4%	$4.8B-12.5%	$5.5B-1.6%	$5.6B+15.8%	$4.9B+63.6%	$3.0B-33.5%	$4.5B-22.3%	$5.7B+8.1%	$5.3B-26.7%	$7.2B
Depreciation & Amortization	N/A	$2.0B+13.0%	$1.8B+15.7%	$1.5B+0.3%	$1.5B-1.6%	$1.5B+16.9%	$1.3B+7.4%	$1.2B-23.4%	$1.6B+2.7%	$1.6B+4.7%	$1.5B+4.8%	$1.4B+3.5%	$1.4B-4.6%	$1.4B-1.1%	$1.5B+6.5%	$1.4B
Stock-Based Compensation	N/A	$626.0M-3.1%	$646.0M+2.7%	$629.0M+69.5%	$371.1M+8.3%	$342.8M+11.3%	$308.1M-1.4%	$312.4M+11.8%	$279.5M-0.6%	$281.3M+10.2%	$255.3M+17.2%	$217.8M+39.6%	$156.0M+7.7%	$144.9M+2.4%	$141.5M-4.0%	$147.4M
Investing Cash Flow	-$25.1B	-$11.0B-18.0%	-$9.3B-30.0%	-$7.2B-90.1%	-$3.8B-31.2%	-$2.9B-26.9%	-$2.3B+72.1%	-$8.1B-524.1%	$1.9B+150.4%	-$3.8B-20.5%	-$3.1B-11813.1%	$26.8M+100.7%	-$3.9B-88.6%	-$2.1B+26.8%	-$2.8B+41.3%	-$4.8B
Financing Cash Flow	$2.6B	-$2.2B-279.9%	$1.2B-64.8%	$3.5B+164.7%	-$5.4B-30.9%	-$4.1B-31.7%	-$3.1B-35.0%	-$2.3B+60.6%	-$5.9B-4240.9%	$142.6M+125.5%	-$559.8M+82.0%	-$3.1B-1769.6%	-$166.4M+95.7%	-$3.8B+13.4%	-$4.4B-86.5%	-$2.4B
Dividends Paid	$5.8B	$5.4B+15.0%	$4.7B+15.0%	$4.1B+15.1%	$3.5B+14.5%	$3.1B+14.9%	$2.7B+11.5%	$2.4B+4.2%	$2.3B+5.5%	$2.2B+1.6%	$2.2B+1.5%	$2.1B+1.2%	$2.1B-0.9%	$2.1B-3.0%	$2.2B+0.3%	$2.2B
Share Buybacks	$6.2B	$4.1B+64.3%	$2.5B+233.3%	$750.0M-50.0%	$1.5B+20.0%	$1.3B+150.0%	$500.0M-88.6%	$4.4B+6.0%	$4.2B+1284.5%	$299.8M-50.0%	$600.1M-19.9%	$749.5M-6.3%	$800.0M-52.9%	$1.7B+135.5%	$721.1M	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$10.7B+246.3%	$5.3B+220.1%	$3.2B+30.3%	$8.8B+138.0%	$3.1B+110.5%	$1.7B+42.9%	$2.5B+892.9%	$3.7B+69.5%
Depreciation & Amortization	$534.0M+11.7%	$509.0M+9.9%	$585.7M+20.7%	$470.3M+0.7%	$478.0M+15.3%	$463.0M+15.6%	$485.2M+25.2%	$466.8M+13.6%
Stock-Based Compensation	N/A	$161.0M+4.5%	N/A	N/A	N/A	$154.0M-3.4%	N/A	N/A
Investing Cash Flow	-$15.4B-739.5%	-$3.9B-16.8%	-$2.8B-45.9%	-$3.0B+25.5%	-$1.8B+16.6%	-$3.4B-184.7%	-$1.9B+34.3%	-$4.0B-30.0%
Financing Cash Flow	$8.4B+776.8%	-$3.5B-351.4%	-$2.9B-1176.6%	$530.8M+151.2%	-$1.2B-180.0%	$1.4B+543.3%	-$225.5M-106.4%	$211.3M-63.1%
Dividends Paid	$1.5B+14.8%	$1.5B+15.0%	$1.3B+15.2%	$1.3B+15.0%	$1.3B+14.9%	$1.3B+15.1%	$1.2B+14.7%	$1.2B+15.2%
Share Buybacks	$1.6B+131.4%	$2.4B+96.3%	$1.5B-26.6%	$708.3M+58.8%	$692.0M	$1.2B	$2.1B	$446.1M

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.

LLY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LLY quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	83.0%+1.7pp	81.3%+2.1pp	79.3%+2.5pp	76.8%+2.6pp	74.2%-3.5pp	77.7%-1.2pp	78.8%+0.6pp	78.2%+0.5pp	77.7%+0.4pp	77.3%+2.5pp	74.8%-0.1pp	74.9%-3.9pp	78.8%0.0pp	78.8%-0.4pp	79.1%
Net Margin	31.7%+8.2pp	23.5%+8.2pp	15.4%-6.5pp	21.9%+2.2pp	19.7%-5.5pp	25.2%-12.0pp	37.3%+22.2pp	15.0%+16.1pp	-1.0%-16.0pp	14.9%+2.9pp	12.1%-0.1pp	12.2%-8.1pp	20.3%+2.2pp	18.1%+0.2pp	17.9%
Return on Equity	77.8%+3.6pp	74.2%+25.6pp	48.6%-10.0pp	58.6%-3.5pp	62.2%-47.6pp	109.8%-209.3pp	319.1%+286.2pp	32.9%+34.6pp	-1.8%-21.3pp	19.5%+3.0pp	16.5%+1.0pp	15.6%-11.0pp	26.6%-1.1pp	27.7%-4.4pp	32.1%
Return on Assets	18.4%+4.9pp	13.5%+5.3pp	8.2%-4.4pp	12.6%+1.2pp	11.4%-1.8pp	13.3%-7.9pp	21.2%+13.8pp	7.4%+7.8pp	-0.4%-7.5pp	7.0%+0.3pp	6.8%+0.2pp	6.6%-6.7pp	13.3%+1.4pp	11.9%-1.0pp	12.9%
Current Ratio	1.58+0.4x	1.15+0.2x	0.94-0.1x	1.05-0.2x	1.23-0.2x	1.40+0.2x	1.16-0.6x	1.73+0.4x	1.32-0.1x	1.37-0.2x	1.53+0.3x	1.22-0.2x	1.47-0.1x	1.550.0x	1.60
Debt-to-Equity	1.54-0.5x	2.00+0.3x	1.70+0.3x	1.38-0.3x	1.71-1.2x	2.94-2.4x	5.30+4.4x	0.94+0.1x	0.86+0.3x	0.60+0.1x	0.55+0.2x	0.35+0.1x	0.24-0.1x	0.370.0x	0.40
Asset Turnover	0.580.0x	0.570.0x	0.530.0x	0.580.0x	0.58+0.1x	0.530.0x	0.57+0.1x	0.490.0x	0.440.0x	0.47-0.1x	0.560.0x	0.54-0.1x	0.660.0x	0.66-0.1x	0.72

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	85.8%+1.5pp	81.9%-0.6pp	82.5%+0.3pp	82.9%+1.9pp	84.3%+3.5pp	82.5%+1.6pp	82.2%+1.4pp	81.0%+0.6pp
Net Margin	30.9%-5.5pp	37.4%+15.7pp	34.4%+1.8pp	31.7%+23.2pp	36.4%+10.1pp	21.7%-3.9pp	32.6%+9.2pp	8.5%+9.1pp
Return on Equity	20.9%-10.0pp	23.7%+6.2pp	25.0%-5.9pp	23.5%+16.7pp	31.0%+9.1pp	17.5%0.0pp	30.9%+10.6pp	6.8%+7.3pp
Return on Assets	5.0%-0.6pp	6.3%+3.3pp	5.9%+0.3pp	4.9%+3.6pp	5.6%+1.5pp	3.1%-0.4pp	5.6%+2.2pp	1.3%+1.4pp
Current Ratio	1.35+0.1x	1.50+0.1x	1.58+0.4x	1.55+0.3x	1.28+0.2x	1.370.0x	1.15+0.2x	1.27+0.2x
Debt-to-Equity	1.41-0.5x	1.26-0.9x	1.54-0.5x	1.72-0.3x	1.87+0.1x	2.19+0.3x	2.00+0.3x	2.04+0.4x
Asset Turnover	0.160.0x	0.170.0x	0.170.0x	0.150.0x	0.150.0x	0.140.0x	0.170.0x	0.150.0x

Not reported in any period shown, so not listed: Operating Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Eli Lilly and Company LLY	FY2025	$65.2B	$20.6B	31.7%	$1.1T	—
Johnson & Johnson JNJ	FY2025	$94.2B	$26.8B	28.5%	$618.1B	37/100
AbbVie Inc. ABBV	FY2025	$61.2B	$4.2B	6.9%	$481.4B	58/100
AstraZeneca PLC AZN	FY2025	$58.7B	$10.2B	17.4%	$246.3B	43/100
Novartis AG NVS	FY2025	N/A	$14.0B	N/A	$272.0B	—

Where Eli Lilly and Company Ranks

Frequently Asked Questions

What is Eli Lilly and Company's annual revenue?

Eli Lilly and Company (LLY) reported $65.2B in total revenue for fiscal year 2025. This represents a 44.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Eli Lilly and Company's revenue growing?

Eli Lilly and Company (LLY) revenue grew by 44.7% year-over-year, from $45.0B to $65.2B in fiscal year 2025.

Is Eli Lilly and Company profitable?

Yes, Eli Lilly and Company (LLY) reported a net income of $20.6B in fiscal year 2025, with a net profit margin of 31.7%.

How much debt does Eli Lilly and Company have?

As of fiscal year 2025, Eli Lilly and Company (LLY) had $7.3B in cash and equivalents against $40.9B in long-term debt.

What is Eli Lilly and Company's gross margin?

Eli Lilly and Company (LLY) had a gross margin of 83.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Eli Lilly and Company's net profit margin?

Eli Lilly and Company (LLY) had a net profit margin of 31.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Eli Lilly and Company pay dividends?

Yes, Eli Lilly and Company (LLY) paid $6.23 per share in dividends during fiscal year 2025.

What is Eli Lilly and Company's return on equity (ROE)?

Eli Lilly and Company (LLY) has a return on equity of 77.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Eli Lilly and Company's operating cash flow?

Eli Lilly and Company (LLY) generated $16.8B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Eli Lilly and Company's total assets?

Eli Lilly and Company (LLY) had $112.5B in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Eli Lilly and Company spend on research and development?

Eli Lilly and Company (LLY) invested $13.3B in research and development during fiscal year 2025.

Does Eli Lilly and Company buy back shares?

Yes, Eli Lilly and Company (LLY) spent $4.1B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Eli Lilly and Company have outstanding?

Eli Lilly and Company (LLY) had 943M shares outstanding as of fiscal year 2025.

What is Eli Lilly and Company's current ratio?

Eli Lilly and Company (LLY) had a current ratio of 1.58 as of fiscal year 2025, which is generally considered healthy.

What is Eli Lilly and Company's debt-to-equity ratio?

Eli Lilly and Company (LLY) had a debt-to-equity ratio of 1.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Eli Lilly and Company's return on assets (ROA)?

Eli Lilly and Company (LLY) had a return on assets of 18.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Eli Lilly and Company's P/E ratio?

Eli Lilly and Company (LLY) trades at 39.4x earnings, its market capitalization divided by net income of $26.7B net income, trailing 12 months to June 30, 2026. The market capitalization is $1.1T as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Eli Lilly and Company's price-to-sales ratio?

Eli Lilly and Company (LLY) trades at 13.2x sales, its market capitalization divided by revenue of $79.7B revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.1T as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Eli Lilly and Company's Piotroski F-Score?

Eli Lilly and Company (LLY) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Eli Lilly and Company's earnings high quality?

Eli Lilly and Company (LLY) has an earnings quality ratio of 0.81x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.